Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 11
2013 10
2014 12
2015 19
2016 29
2017 14
2018 16
2019 22
2020 22
2021 26
2022 18
2023 15
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER, Alibegovic AC, Corcoy R, Dunne F, Feig DS, Hod M, Jia T, Kalyanam B, Kar S, Kautzky-Willer A, Marchesini C, Rea RD, Damm P; EXPECT study group. Mathiesen ER, et al. Lancet Diabetes Endocrinol. 2023 Feb;11(2):86-95. doi: 10.1016/S2213-8587(22)00307-2. Epub 2023 Jan 6. Lancet Diabetes Endocrinol. 2023. PMID: 36623517 Clinical Trial.
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic profile compared with first-generation basal insulins, but there are few data regarding its use during pregnancy. In this non-inferiority tr …
BACKGROUND: Insulin degludec (degludec) is a second-generation basal insulin with an improved pharmacokinetic-pharmacodynamic …
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S, Atkin S, Cervera A, Das AK, Demir O, Demir T, Fariduddin M, Vo KT, Ku BJ, Kumar A, Latif ZA, Malek R, Matawaran BJ, Mehta R, Tran NQ, Panelo A, Ruder S, Saldana JR, Shaikh KA, Shakya A, Shrestha D, Unnikrishnan AG. Kalra S, et al. Adv Ther. 2018 Jul;35(7):928-936. doi: 10.1007/s12325-018-0712-2. Epub 2018 May 23. Adv Ther. 2018. PMID: 29796928 Review.
Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp). ...
Insulin degludec/aspart (IDegAsp) is the first soluble insulin co-formulation, combining a long-acting insulin …
Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
Mehta R, Chen R, Hirose T, John M, Kok A, Lehmann R, Unnikrishnan AG, Yavuz DG, Fulcher G. Mehta R, et al. Diabetes Obes Metab. 2020 Nov;22(11):1961-1975. doi: 10.1111/dom.14128. Epub 2020 Aug 12. Diabetes Obes Metab. 2020. PMID: 32618405 Free PMC article. Review.
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec, which provides long-lasting basal insulin coverage, and insulin aspart, which targets postprandial glycaemia. ...
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec, which prov …
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
Demir T, Turan S, Unluhizarci K, Topaloglu O, Tukek T, Gogas Yavuz D. Demir T, et al. Front Endocrinol (Lausanne). 2021 Mar 12;12:616514. doi: 10.3389/fendo.2021.616514. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33776914 Free PMC article. Review.
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), which provides long-lasting basal insulin coverage, and insulin aspart (IAsp), which targets post-prandial glucose. ...
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (IDeg), whi …
Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
Dardano A, Bianchi C, Del Prato S, Miccoli R. Dardano A, et al. Vasc Health Risk Manag. 2014 Aug 5;10:465-75. doi: 10.2147/VHRM.S40097. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 25143741 Free PMC article. Review.
The most attractive insulin treatment approach should meet the patients' preference, rather than demanding patients to change or adapt their lifestyle. Insulin degludec/insulin aspart (IDegAsp) is a new combination, formulated with ultra-long-acting insuli …
The most attractive insulin treatment approach should meet the patients' preference, rather than demanding patients to change or adapt their …
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, Mathieu C, Rosenstock J, Woo V, Klonoff DC. Russell-Jones D, et al. Lancet. 2023 Nov 4;402(10413):1636-1647. doi: 10.1016/S0140-6736(23)02179-7. Epub 2023 Oct 17. Lancet. 2023. PMID: 37863084 Free article. Clinical Trial.
BACKGROUND: ONWARDS 6 compared the efficacy and safety of once-weekly subcutaneous insulin icodec (icodec) and once-daily insulin degludec (degludec) in adults with type 1 diabetes. METHODS: This 52-week (26-week main phase plus a 26-week safety extension), randomis …
BACKGROUND: ONWARDS 6 compared the efficacy and safety of once-weekly subcutaneous insulin icodec (icodec) and once-daily insulin …
Functional insulin aspart/insulin degludec-based microneedles for promoting postprandial glycemic control.
Chen BZ, Li WX, Feng YH, Zhang XP, Jiao J, Li ZL, Nosrati-Siahmazgi V, Shahbazi MA, Guo XD. Chen BZ, et al. Acta Biomater. 2023 Nov;171:350-362. doi: 10.1016/j.actbio.2023.09.010. Epub 2023 Sep 13. Acta Biomater. 2023. PMID: 37708925
Insulin aspart (IAsp) and insulin degludec (IDeg), as the third generation of insulin, have a faster onset time or a more durable action period, which may simulate the secretion of insulin under physiological conditions. ...
Insulin aspart (IAsp) and insulin degludec (IDeg), as the third generation of insulin, have a faster onset time or a mo …
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.
Atkin S, Javed Z, Fulcher G. Atkin S, et al. Ther Adv Chronic Dis. 2015 Nov;6(6):375-88. doi: 10.1177/2040622315608646. Ther Adv Chronic Dis. 2015. PMID: 26568812 Free PMC article. Review.
In particular, the chemical properties of insulin degludec have allowed the development of a soluble co-formulation with prandial insulin aspart (insulin degludec/insulin aspart) that provides basal insulin coverage for at least 24 h with …
In particular, the chemical properties of insulin degludec have allowed the development of a soluble co-formulation with prand …
Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis.
Edina BC, Tandaju JR, Wiyono L. Edina BC, et al. Cureus. 2022 Jun 2;14(6):e25612. doi: 10.7759/cureus.25612. eCollection 2022 Jun. Cureus. 2022. PMID: 35784980 Free PMC article. Review.
Treatment intensification using separate basal and bolus injections increased the number of injections and reduced cost-effectivity, leading to decreased compliance and failure of glycemic control. Insulin Degludec/Insulin Aspart (IDegAsp), a novel premix of …
Treatment intensification using separate basal and bolus injections increased the number of injections and reduced cost-effectivity, leading …
The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia.
Glastras SJ, Cohen N, Dover T, Kilov G, MacIsaac RJ, McGill M, Fulcher GR. Glastras SJ, et al. J Clin Med. 2020 Apr 11;9(4):1091. doi: 10.3390/jcm9041091. J Clin Med. 2020. PMID: 32290465 Free PMC article. Review.
Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting insulin analogue (basal plus one or more prandial doses; multiple daily injections) or by a switch to premixed insulin. Insulin d …
Treatment intensification in people with type 2 diabetes following failure of basal insulin commonly involves the addition of a rapid-acting …
180 results